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To the Editor: In a recent issue of the Journal, Praga et al.1
reported their experience with tacrolimus monotherapy in
patients with idiopathic membranous nephropathy. The
authors concluded that tacrolimus was a very useful
therapeutic option. This conclusion was based on the
findings of a higher remission rate and a reduced risk of
deterioration of renal function in the treated patients.
However, some of the reported data need clarification.
(1) This study may not be applicable to routine clinical
practice. Most studies included patients with
relatively recent onset of disease. In the study of
Praga et al., the interval between diagnosis and
inclusion in the study was 45 months in the control
group and 58 months in the treated group. Most
patients with idiopathic membranous nephropathy
will develop remission or renal failure within 3 years
after presentation.2
(2) The information on follow-up time is lacking. The
study included patients studied between January
2003 and September 2006. It is therefore unlikely
that all patients have been followed for 30 months.
This information is needed to read Figure 3
correctly. The cumulative incidence of a relapse
may be higher than shown.
(3) The power calculation suggests that the study was
powered to determine differences in remission rate
and not differences in renal failure rate.
Moreover the results are overrated and so is the
conclusion. Tacrolimus treatment did not result in persistent
remissions, since the number of remissions at the end of
follow-up was similar in the treated and the control groups.
The shortlasting decrease of proteinuria may be the
consequence of a hemodynamic effect. Correct interpretation
of these results would be that 18 months of treatment with
tacrolimus did not influence the outcome with respect to
remissions at the end of follow-up. Certainly, the conclusion
reached by the authors is driven by the observed differences
in renal function deterioration. In the control group, six
patients developed a 50% increase of serum creatinine level as
compared to only one in the treated group. One normally
would have expected that differences in renal survival become
evident with longer duration of follow-up. However, Figure 5
shows that the differences between the groups were already
apparent at 6 months after randomization, and that there was
no further change in renal function after 12 months. Patients
who reached the renal failure end point were characterized by
higher age, higher initial serum creatinine concentration, and
higher levels of proteinuria. Table 1 clearly indicates that the
treated and the control groups were not balanced with respect
to these parameters. The control group contained more patients
aged 450 years (48 vs 24%), more patients with glomerular
filtration rate o60 ml min1 (17 vs 4%), and more patients
with severe proteinuria (43 vs 32%). These differences must not
be overlooked; the b error is high in a small-sized study.
Therefore, this study does not allow to conclude that tacro-
limus improves renal survival in patients with idiopathic membra-
nous nephropathy. Thus far, only alkylating agents have been
proven effective in reducing the risk of end-stage renal disease.2–4
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To the Editor: There is little doubt that coronary calcification
is associated with cardiovascular mortality.
Also, plausible biologic explanations implying disturbed
calcium phosphate metabolisms are available. A practicing
nephrologist may therefore be tempted to switch from the
traditional calcium-based chelators to other alternatives. One
of those attractive alternatives is sevelamer, which has been
shown to reduce coronary calcification.
However, coronary calcification is only a surrogate
marker, and clinical trials with improvement of surrogate
markers may not necessarily be associated with better clinical
outcomes. Worse still, in some of them, just to cite the
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example of the recently interrupted ILLUMINATOR trial1
and the now historical CAST trial,2 an increase in mortality
was observed. Data on clinical outcomes are therefore badly
needed for sevelamer.
In the 1 March issue of this journal, Block et al.3
attempted to present the scientific community with mortality
data. Briefly, 127 hemodialysed patients had been rando-
mized either to sevelamer or calcium-based phosphate
chelation for 18 months, and all-cause mortality was assessed
after a median follow-up of 44 months. Thirty-four deaths
were observed, 11 in the sevelamer group and 23 in the other
group. This difference was statistically different after adjust-
ment for a certain number of parameters, and the authors
concluded that treatment with sevelamer was associated with
a survival benefit.
In our opinion, these results and the conclusion drawn
must be interpreted with caution for the following reasons:
First, after 18 months of follow-up, phosphate binders were
prescribed ‘at the discretion of their primary nephrologist.’
The trial was therefore no longer under control, and the
authors had consequently no reliable information on the
nature of the drugs actually taken by the participants.
Second, details about ascertainment of mortality and its
causes were so scarce that the reader may wonder whether
this had been initially planned as an end point at all.
Indeed, in the introduction of their present paper, the
authors stated that ‘all-cause mortality was a secondary
endpoint of a randomized trial previously reported.’ This end
point is in fact not indicated in the cited paper.4
Furthermore, if this had been a prespecified end point, then
one would wonder why survival data had not been presented
in the first publication.
Finally, if sevelamer is to save lives, based on its action
mechanisms on coronary calcification, then cardiovascular
end points would be the first to be assessed and not the all-
cause mortality.
In conclusion, these points should be clarified by the
authors to allow a reliable and meaningful interpretation of
their data. Misinterpretation of these data could raise false
hopes among patients, mislead health policy makers, and
ultimately induce inappropriate use of public resources.
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We agree with Drs Nguyen and Descombes1 that there is
substantial evidence to suggest a link between vascular calcifi-
cation and mortality and his statement that there is a plausible
link between calcium and phosphorus metabolism and vascular
calcification. As Dr Nguyen also states, it has now been shown
that sevelamer can slow vascular calcification compared to
patients treated with calcium-based binders. While we agree
that large randomized trials are greatly needed in this area of
dialysis care, our trial, despite its limitations, adds one more
piece of data to this complex problem. As we await more data,
we are faced with providing our patients with the best care
possible. We remind the readers that calcium was chosen as a
binder when it became clear that aluminum was causing toxi-
city. There is no literature demonstrating the safety of calcium
in dialysis patients. While health policy makers will continue to
struggle with the cost of the care of dialysis patients, we feel that
the overwhelming evidence suggests that calcium loading is
detrimental to the well-being of dialysis patients. The mortality
data from the RIND trial are but one small piece of evidence.
As we state in this paper, after the randomized portion of the
trial (18 months), patients were prescribed phosphate binders at
the discretion of their primary nephrologist. We agree that
this may have affected our ability to discern differences bet-
ween the two randomized groups; however, this bias would
always lead to an increased likelihood of finding no significant
differences between the groups rather than the alternative.
We are uncertain as to why there is question as to our
ability to ascertain mortality status nor what kind of details are
requested in determining whether subjects were alive or dead.
The fact that the mortality end point was not discussed in the
initial paper is entirely a result of the initial paper focusing
exclusively on the primary end point of the randomized trial—
coronary calcification. As we point out, the strength of our
study is in the duration of follow-up prior to ascertainment of
mortality, and our conclusions would have been erroneously
modified had we reported mortality at 18 months as Drs
Nguyen and Descombes suggest.
As we clearly state in the March 2007 paper, all-cause
mortality was a prespecified secondary end point (and not
a post hoc analysis) at the time of the submission of the
study protocol to our Internal Review Board.
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